Inhibition of HDAC2 sensitises antitumour therapy by promoting NLRP3/GSDMD-mediated pyroptosis in colorectal cancer

Abstract

• Silencing of NLRP3 limits the GSDMD-dependent pyroptosis in colorectal cancer.

• HDAC2-mediated histone deacetylation leads to epigenetic silencing of NLRP3.

• HDAC2 suppresses the NLRP3 transcription by inhibiting the formation of H3K27ac/BRD4/p-P65 complex.

• Targeting HDAC2 activates pyroptosis and enhances therapeutic effect.

Keywords

colorectal cancer / H3K27ac / HDAC2 / NLRP3 / pyroptosis

References

[1] MorganE, ArnoldM, GiniA, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72:338-344.

[2] CiardielloF, Ciardiello D, MartiniG, NapolitanoS, Tabernero J, CervantesA. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022;72:372-401.

[3] CervantesA, AdamR, RosellóS, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:10-32.

[4] GrotheyA, BlayJY, PavlakisN, Yoshino T, BruixJ. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993.

[5] AzwarS, SeowHF, AbdullahM, Faisal Jabar M, MohtarrudinN. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology (Basel). 2021;10:854.

[6] HeinemannV, von Weikersthal LF, DeckerT, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065-1075.

[7] LoteH, Starling N, PihlakR, GerlingerM. Advances in immunotherapy for MMR proficient colorectal cancer. Cancer Treat Rev. 2022;111:102480.

[8] TanY, ChenQ, LiX, et al. Pyroptosis: a new paradigm of cell death for fighting against cancer. J Exp Clin Cancer Res. 2021;40:153.

[9] ZhangZ, ZhouY, ZhaoS, Ding L, ChenB, ChenY. Nanomedicine-enabled/augmented cell pyroptosis for efficient tumor nanotherapy. Adv Sci (Weinh). 2022;9:e2203583.

[10] WeiX, XieF, ZhouX, et al. Role of pyroptosis in inflammation and cancer. Cell Mol Immunol. 2022;19:971-992.

[11] LiYT, TanXY, MaLX, et al. Targeting LGSN restores sensitivity to chemotherapy in gastric cancer stem cells by triggering pyroptosis. Cell Death Dis. 2023;14:545.

[12] WangY, GaoW, ShiX, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547:99-103.

[13] ShiJ, ZhaoY, WangK, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015;526:660-665.

[14] YangJ, LiuZ, WangC, et al. Mechanism of gasdermin D recognition by inflammatory caspases and their inhibition by a gasdermin D-derived peptide inhibitor. Proc Natl Acad Sci U S A. 2018;115:6792-6797.

[15] LuF, LanZ, XinZ, et al. Emerging insights into molecular mechanisms underlying pyroptosis and functions of inflammasomes in diseases. J Cell Physiol. 2020;235:3207-3221.

[16] FangY, TangY, HuangB. Pyroptosis: a road to next-generation cancer immunotherapy. Semin Immunol. 2023;68:101782.

[17] ShadabA, Mahjoor M, Abbasi-KolliM, AfkhamiH, Moeinian P, SafdarianAR. Divergent functions of NLRP3 inflammasomes in cancer: a review. Cell Commun Signal. 2023;21:232.

[18] TarteyS, Kanneganti TD. Differential role of the NLRP3 inflammasome in infection and tumorigenesis. Immunology. 2019;156:329-338.

[19] JungG, Hernández-Illán E, MoreiraL, BalaguerF, GoelA. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol. 2020;17:111-130.

[20] ShettyMG, PaiP, DeaverRE, Satyamoorthy K, BabithaKS. Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy. Pharmacol Res. 2021;170:105695.

[21] HaringM, Offermann S, DankerT, HorstI, Peterhansel C, StamM. Chromatin immunoprecipitation: optimization, quantitative analysis and data normalization. Plant Methods. 2007;3:11.

[22] YaoY, LiuC, WangB, et al. HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. Cancer Lett. 2022;533:215595.

[23] BuenrostroJD, GiresiPG, ZabaLC, Chang HY, GreenleafWJ. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat Methods. 2013;10:1213-1218.

[24] YangC, MaL, XiaoD, Ying Z, JiangX, LinY. Integration of ATAC-Seq and RNA-Seq identifies key genes in light-induced primordia formation of Sparassis latifolia. Int J Mol Sci. 2019;21:185.

[25] QiZP, Yalikong A, ZhangJW, et al. HDAC2 promotes the EMT of colorectal cancer cells and via the modular scaffold function of ENSG00000274093.1. J Cell Mol Med. 2021;25:1190-1197.

[26] JeongJB, LeeSH. Protocatechualdehyde possesses anti-cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochem Biophys Res Commun. 2013;430:381-386.

[27] XiY, XuP. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol. 2021;14:101174.

[28] YanH, LuoB, WuX, et al. Cisplatin induces pyroptosis via activation of MEG3/NLRP3/caspase-1/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17:2606-2621.

[29] WestbomC, Thompson JK, LeggettA, et al. Inflammasome modulation by chemotherapeutics in malignant mesothelioma. PLoS One. 2015;10:e0145404.

[30] JohnsonDC, Taabazuing CY, OkondoMC, et al. DPP8/DPP9 inhibitor-induced pyroptosis for treatment of acute myeloid leukemia. Nat Med. 2018;24:1151-1156.

[31] ZhangY, LiF, WangL, Lou Y. A438079 affects colorectal cancer cell proliferation, migration, apoptosis, and pyroptosis by inhibiting the P2×7 receptor. Biochem Biophys Res Commun. 2021;558:147-153.

[32] FengWQ, ZhangYC, XuZQ, et al. IL-17A-mediated mitochondrial dysfunction induces pyroptosis in colorectal cancer cells and promotes CD8 + T-cell tumour infiltration. J Transl Med. 2023;21:335.

[33] JuM, BiJ, WeiQ, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform. 2021;22:bbaa345.

[34] SharmaBR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases. Nat Immunol. 2021;22:550-559.

[35] XuJ, Núñez G. The NLRP3 inflammasome: activation and regulation. Trends Biochem Sci. 2023;48:331-344.

[36] ZhuP, MartinE, MengwasserJ, Schlag P, JanssenKP, GöttlicherM. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004;5:455-463.

[37] BacklundMG, MannJR, HollaVR, et al. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res. 2008;68:9331-9337.

[38] MariadasonJM. HDACs and HDAC inhibitors in colon cancer. Epigenetics. 2008;3:28-37.

[39] BartosovicM, KabbeM, Castelo-BrancoG. Single-cell CUT&Tag profiles histone modifications and transcription factors in complex tissues. Nat Biotechnol. 2021;39:825-835.

[40] ZhengX, Diktonaite K, QiuH. Epigenetic reader bromodomain-containing protein 4 in aging-related vascular pathologies and diseases: molecular basis, functional relevance, and clinical potential. Biomolecules. 2023;13:1135.

[41] DongJ, LiJ, LiY, MaZ, YuY, WangCY. Transcriptional super-enhancers control cancer stemness and metastasis genes in squamous cell carcinoma. Nat Commun. 2021;12:3974.

[42] NordJA, Wynia-Smith SL, GehantAL, et al. N-terminal BET bromodomain inhibitors disrupt a BRD4-p65 interaction and reduce inducible nitric oxide synthase transcription in pancreatic β-cells. Front Endocrinol (Lausanne). 2022;13:923925.

[43] TangW, ZhouW, XiangL, et al. The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer. Nat Commun. 2019;10:663.

[44] ConteM, Di Mauro A, CapassoL, et al. Targeting HDAC2-mediated immune regulation to overcome therapeutic resistance in mutant colorectal cancer. Cancers (Basel). 2023;15:1960.

[45] SinghM, KumarV, SehrawatN, et al. Current paradigms in epigenetic anticancer therapeutics and future challenges. Semin Cancer Biol. 2022;83:422-440.

[46] BiersackB, PolatS, HöpfnerM. Anticancer properties of chimeric HDAC and kinase inhibitors. Semin Cancer Biol. 2022;83:472-486.

[47] RaiS, KimWS, AndoK, et al. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. Haematologica. 2023;108:811-821.

[48] GromekSM, de Mayo JA, MaxwellAT, et al. Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity. Bioorg Med Chem. 2016;24:5183-5196.

[49] ZhangT, WeiD, LuT, et al. CAY10683 and imatinib have synergistic effects in overcoming imatinib resistance via HDAC2 inhibition in chronic myeloid leukemia. RSC Adv. 2020;10:828-844.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.